You are here: Home > Institute of Excellence (CPD) > CPD Events > Drought Breaker: New GA Treatments to Impact Optometry

Drought Breaker: New GA Treatments to Impact Optometry

Provider: Mivision

Contact: Nikki Byrne, [E] nikki@mivision.com.au, [P] 02 8336 8616

Activity Outline

One of the defining moments in ophthalmology was the introduction of intravitreal anti-VEGFs to treat neovascular age-related macular degeneration (nAMD). Now, eye care professionals outside the United States await news from their respective regulatory bodies about the approval of the newest intravitreal injection (IVI) agents, pegcetacoplan and avacincaptad pegol. Given the green light by the United States Food and Drug Administration (FDA) last year, these drugs represent the first-ever treatments for geographic atrophy (GA) – and the first real hope for clinicians and patients alike.

So, what would a post-approval patient pathway look like, and how can we manage their expectations?

Learning Objectives

  • Be aware of the GA treatment options awaiting TGA approval
  • Understand the pathology, symptoms, and functional impact of GA
  • Be able to identify GA using OCT
  • Describe an ideal management pathway for patients with GA
  • Realise the role of optometry in screening, referring on, counselling, and maintaining communication between patients with GA and retinal specialists

Max CPD hours awarded: 1.25

Session Information

Name
Drought Breaker: New GA Treatments to Impact Optometry
Clinical?
Yes
Interactive?
No
Therapeutic?
Yes
Duration of CPD Session/Module
0.75
Duration of CPD Session/Module inclusive of Assessment Component
1.25

Acknowledgement of Country

In the spirit of reconciliation Optometry Australia acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respects to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.